Vycor Medical, Inc. Announces Earnings Results for the Second Quarter Ended June 30, 2021
August 16, 2021 at 03:06 pm EDT
Share
Vycor Medical, Inc. announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced sales was USD 491,427 compared to USD 244,266 a year ago. Operating income was USD 23,489 compared to operating loss of USD 199,358 a year ago. Net loss was USD 9,374 compared to USD 248,887 a year ago. For the half year, sales was USD 787,176 compared to USD 574,505 a year ago. Operating loss was USD 183,360 compared to USD 346,059 a year ago. Net loss was USD 252,293 compared to USD 423,835 a year ago. Basic loss per share was USD 0.01 compared to USD 0.02 a year ago.
Vycor Medical, Inc. provides surgical and therapeutic solutions. The Company designs, develops and markets neurological medical devices and therapies. The Company operates through two segments: Vycor Medical and NovaVision. The Vycor Medical segment designs, develops and markets medical devices for use in neurosurgery. The NovaVision segment provides non-invasive rehabilitation therapies for those who have vision disorders resulting from neurological brain damage such as that caused by a stroke. Vycor Medical's product Vycor Medical's ViewSite Brain Access System (VBAS) is a next generation retraction and access system. Vycor Medical focuses on brain and cervical surgical access systems for sale to hospitals and medical professionals. NovaVision's products include Vision Restoration Therapy (VRT), NeuroEyeCoach and Neuro-Eye Therapy (NeEt). The Company operates in the United States and Europe.
VYCOR MEDICAL, INC. 
